MDMA: Difference between revisions
No edit summary |
No edit summary Tag: visualeditor |
||
| Line 12: | Line 12: | ||
MDMA is a "breakthrough" therapy for PTSD.<ref>Mitchell, Jennifer M., Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot’alora G., et al. “MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.” Nature Medicine 27, no. 6 (June 1, 2021): 1025–33. https://doi.org/10.1038/s41591-021-01336-3.</ref> | MDMA is a "breakthrough" therapy for PTSD.<ref>Mitchell, Jennifer M., Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot’alora G., et al. “MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.” Nature Medicine 27, no. 6 (June 1, 2021): 1025–33. https://doi.org/10.1038/s41591-021-01336-3.</ref> | ||
MDMA has a "strong bias toward the positive end of the affective spectrum, deeply heart-full, centered psychological insight and self-aceptance, and tends to produce less visual imagery or 'cosmic' breakthroughs or metaphysical disorientation."<ref>Olivetti, Katherine. “Dimensions of the Psyche.” ''Jung Journal'' 9, no. 4 (October 2, 2015): 98–124. <nowiki>https://doi.org/10.1080/19342039.2015.108693</nowiki> p. 103</ref> | MDMA has a "strong bias toward the positive end of the affective spectrum, deeply heart-full, centered psychological insight and self-aceptance, and tends to produce less visual imagery or 'cosmic'breakthroughs or metaphysical disorientation."<ref>Olivetti, Katherine. “Dimensions of the Psyche.” ''Jung Journal'' 9, no. 4 (October 2, 2015): 98–124. <nowiki>https://doi.org/10.1080/19342039.2015.108693</nowiki> p. 103</ref> | ||
'''Action and Measurement''' | |||
The negative experience of "comedowns", colloquially known as "Blue Mondays," are often anecdotally reported by people who take MDMA. Research by Sessa et al. suggests that MDMA comedowns do not exist in a clinical environment and should instead be attributed to improper dosing and illicit sourcing. <ref>Ben Sessa et al., “Debunking the Myth of ‘Blue Mondays’: No Evidence of Affect Drop after Taking Clinical MDMA,” ''Journal of Psychopharmacology'' 36, no. 3 (March 2022): 360–67, <nowiki>https://doi.org/10.1177/02698811211055809</nowiki>.</ref> | |||
==Effects== | ==Effects== | ||
Revision as of 18:47, 6 Ocak 2023
MDMA is an extremely powerful Entactogen that temporarily suppresses the body's fear and anxiety response thus enabling one to recognize and process even deeply buried traumatic experiences.
List of Connection Supplements
Connection Supplement > 5-MEO DMT, Ayahuasca, Cannabis, Chloroform, DMT, Datura, Haoma, Kaneh Bosm, Kava, Ketamine, Kykeon, LSD, MDMA, Maikua, Manna, Nitrous Oxide, Peyote, Psilocybin Mushroom, Santa Rosa, Soma, Tobacco, Yaqona
Notes
MDMA is not a recreational drug and should not be used as such. MDMA is a powerful psychoactive that is extremely useful for healing even deep trauma.
MDMA is a "breakthrough" therapy for PTSD.[1]
MDMA has a "strong bias toward the positive end of the affective spectrum, deeply heart-full, centered psychological insight and self-aceptance, and tends to produce less visual imagery or 'cosmic'breakthroughs or metaphysical disorientation."[2]
Action and Measurement
The negative experience of "comedowns", colloquially known as "Blue Mondays," are often anecdotally reported by people who take MDMA. Research by Sessa et al. suggests that MDMA comedowns do not exist in a clinical environment and should instead be attributed to improper dosing and illicit sourcing. [3]
Effects
Footnotes
- ↑ Mitchell, Jennifer M., Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot’alora G., et al. “MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.” Nature Medicine 27, no. 6 (June 1, 2021): 1025–33. https://doi.org/10.1038/s41591-021-01336-3.
- ↑ Olivetti, Katherine. “Dimensions of the Psyche.” Jung Journal 9, no. 4 (October 2, 2015): 98–124. https://doi.org/10.1080/19342039.2015.108693 p. 103
- ↑ Ben Sessa et al., “Debunking the Myth of ‘Blue Mondays’: No Evidence of Affect Drop after Taking Clinical MDMA,” Journal of Psychopharmacology 36, no. 3 (March 2022): 360–67, https://doi.org/10.1177/02698811211055809.
